



Mayne Pharma Group Limited


Wilson HTM Rapid Insights Investor Conference
2 June 2016




Mayne Pharma overview

- Australian-listed specialty pharmaceutical company, headquartered in Adelaide
- Develops and manufactures generic and proprietary pharmaceuticals which are distributed globally either directly or through distribution partners
- Fully-integrated US operations across contract services, generic and branded products
- Product portfolio and pipeline characterised by high barriers to entry – DEA regulated molecules, high potent, modified-release and semi-solid
 - 30+ molecules marketed globally across 100 different presentations
 - 35+ pipeline products targeting US markets >US\$6.5bn
- 1H16 revenue of A\$127m and EBITDA of A\$43m¹
- Products sold in 10+ countries
- 125+ contract service clients
- 700 staff


Revenue by geography (1H16)



Revenue by division (1H16)



Revenue by channel (1H16)



Mayne Pharma business segments & financials



	Generic Products (GPD)	Specialty Brands (SBD)	Metrics Contract Services (MCS)	Mayne Pharma International (MPI)
Description	Develops, manufactures, markets and distributes generic products in the US	Markets and distributes specialty branded products in the US	Provides contract pharmaceutical development and analytical services to third party customers globally	Develops, manufactures, markets and distributes branded and generic products globally (excl. US)

Key products & services


- Amiodarone
- BAC
- Doxycycline
- Erythromycin
- Liothyronine
- Methamphetamine
- Nystatin
- Oxycodone

- Doryx™


- Analytical services
- Formulation Development

- Doryx™
- Eryc™
- Kapanol™/Kadian™
- Lozanoc™
- Magnoplasm™
- Range of injectable products

Group revenue (A\$m)




Group underlying EBITDA and EBITDA margins¹ (A\$m)



1. Refer to reconciliation table in earnings release dated 26 February 2016 for adjustments to EBITDA

Mayne Pharma's international footprint



Investing for growth – Greenville, NC site expansion




Construction status as at May 2016

- New 125,000ft² oral solid dose manufacturing facility construction commenced October 2015
- Commercial production to migrate to new building
- Product launches from scheduled for January 2018
- Adds multi-particulate layering, bead coating fluid bed technology and organic solvent coating capacities

Investing for growth – research and development

- Diverse capabilities
 - Oral (tablets and capsules)
 - Topical (ointments, solutions and powders)
 - Potent compounds
 - DEA controlled substances
 - Unstable compounds
 - Modified-release
 - Products with poor bioequivalence
- R&D investment target of 10-12% of revenue annually
- Focus on higher value and high barrier to entry product opportunities in the US
- 35+ pipeline products targeting US markets with annual sales >US\$6.5bn¹ of which 13 are pending approval
- 10+ products under development targeting AU markets with sales > A\$100m

US Pipeline statistics – IMS market size (US\$bn)¹



Number of products

3

13

19+

35+

US pipeline by type (number)

Orals - controlled substance	11
Orals - modified-release	9
Orals - potent	6
Semi-solid	2


FY16 key product highlights

Timing	Event	Country
May 2016	Doryx™ MPC 60mg and 120mg tablets approved by FDA	US
May 2016	Invested US\$2.8m in Hedgepath Pharmaceuticals to support ongoing clinical program using Mayne Pharma's patented oral formulation of itraconazole to treat certain cancers.	US
May 2016	Itraisdin (Mayne Pharma's 50mg SUBA - itraconazole capsule) launched in Germany by ISDIN	Germany
Apr 2016	Oxycodone 10mg and 20mg tablets approved by FDA	US
Apr 2016	Temozolomide capsule approved by FDA (In-licensed product)	US
Mar 2016	Launched Noradrenaline injectable in Australia – first generic competitor	Australia
Mar 2016	Liothyronine asset acquisition from Perrigo	US
Dec 2015	Launched BACCP capsule in the US	US
Oct 2015	Launched Oxycodone tablet in Australia	Australia
Aug 2015	Launched Doryx™ 50mg tablet in the US	US
Aug 2015	Launched generic BAC tablet in the US (in-licensed product)	US


Doryx update

- Doryx franchise (50mg and 200mg) market share ~7% of the tetracycline addressable market¹
 - Solodyn TRx market share gain reflects inclusion of business previously not reported by IMS
- Doryx MPC approved 20 May 2016
 - New formulation that incorporates a modified polymer coat designed to further retard the release of doxycycline in the acidic environment of the stomach
 - Launch 3Q 2016
- Mylan launched doxycycline hyclate delayed release (DR) tablets (50mg and 200mg) in May 2016 and awarded 180 days of market exclusivity
- Mayne Pharma launched generic doxycycline hyclate DR tablets (50mg and 200mg) in May 2016 (authorised generic)

Doryx weekly prescription (TRx) data



TRx market share of key brands (tetracycline market)





Mayne Pharma has an experienced leadership team



Scott Richards
Chief Executive Officer
Actavis, Hospira, FH Faulding & Co.



Stefan Cross
President, Mayne Pharma USA
Hospira, FH Faulding & Co



Mark Cansdale
Group CFO, Company Secretary
Vision Systems, McMillan Shakespeare



Dr Ilana Stancovski
Chief Scientific Officer
Actavis, Pfizer



Craig Boyd
EVP, Generic Products
Hospira, Mylan, Novartis



Andy McClenaghan
EVP, Specialty Brands
Warner Chilcott, Procter & Gamble



Eric Evans
CFO, Mayne Pharma USA
Patheon, Novartis, Sandoz



John Ross
EVP, Metrics Contract Services
CPL, Eli Lilly



Peter Paltoglou
EVP, Corporate Development
Credit Suisse, Hindal



Kate Rintoul
EVP and General Counsel
Minter Ellison, Shell

Significant opportunities to drive growth

1. US retail generics maximization

- Optimize market penetration of product portfolio
- Approval and launch of filed FDA products
- Control manufacture, distribution and sales and marketing of key franchises
- Efficient and reliable product sourcing, manufacturing and supply
- Portfolio expansion through growing product pipeline

2. Expand US branded specialty franchise portfolio

- Develop US specialty dermatology franchise by leveraging Doryx™ and pipeline of future products
- Build new specialty therapeutic platforms that leverage the Company's development and manufacturing capabilities

3. Optimize and grow Metrics Contract Services

- Enhance operational efficiencies and client experience
- Globalize customer base
- Introduce high value manufacturing services following Greenville, NC site expansion

4. R&D maximization

- Portfolio selection that leverages drug delivery expertise in complex generics and specialty products
- Selective Paragraph IV filings in the US
- Development of Suba-Itraconazole in cancer through alliance with HedgePath

5. Strategic acquisitions, licensing and partnerships

- In-licensing niche generic or specialty products in Australia and the US
- Commercialize specialty products such as Lozanoc™ through out-licensing arrangements in key markets to broaden global footprint
- Product and enterprise acquisitions with strong growth potential, complementary assets and technologies
- Build an injectable portfolio and branded specialty franchise in Australia

**A specialty pharmaceutical company
with an increasingly diversified
portfolio of products, technologies and
footprint**

You deserve tomorrow.